These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 24739128)
21. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation. Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924 [TBL] [Abstract][Full Text] [Related]
22. Factors associated with non-adherence to specific allergen immunotherapy in management of respiratory allergy. Mahesh PA; Vedanthan PK; Amrutha DH; Giridhar BH; Prabhakar AK Indian J Chest Dis Allied Sci; 2010; 52(2):91-5. PubMed ID: 20578401 [TBL] [Abstract][Full Text] [Related]
23. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Bussmann C; Maintz L; Hart J; Allam JP; Vrtala S; Chen KW; Bieber T; Thomas WR; Valenta R; Zuberbier T; Sager A; Novak N Clin Exp Allergy; 2007 Sep; 37(9):1277-85. PubMed ID: 17845407 [TBL] [Abstract][Full Text] [Related]
24. Bronchial allergen provocation: a useful method to assess the efficacy of specific immunotherapy in children. Rosewich M; Arendt S; El Moussaoui S; Schulze J; Schubert R; Zielen S Pediatr Allergy Immunol; 2013 Aug; 24(5):434-40. PubMed ID: 23578317 [TBL] [Abstract][Full Text] [Related]
25. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373 [TBL] [Abstract][Full Text] [Related]
26. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? Nelson HS J Allergy Clin Immunol Pract; 2014; 2(2):144-9; quiz 150-1. PubMed ID: 24607040 [TBL] [Abstract][Full Text] [Related]
31. Sublingual immunotherapy for treating respiratory allergy: a review on its effectiveness and suitability. Incorvaia C; Fuiano N; Leo G Clin Ter; 2010; 161(6):543-7. PubMed ID: 21181085 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368 [TBL] [Abstract][Full Text] [Related]
33. Cost of subcutaneous immunotherapy in a large insured population in the United States. Mao J; Heithoff KA; Koep E; Murphy T; Hammerby E Curr Med Res Opin; 2019 Feb; 35(2):351-358. PubMed ID: 30091647 [TBL] [Abstract][Full Text] [Related]
34. Specific allergy immunotherapy for allergic rhinitis: subcutaneous and sublingual. Cox L; Wallace D Immunol Allergy Clin North Am; 2011 Aug; 31(3):561-99. PubMed ID: 21737043 [TBL] [Abstract][Full Text] [Related]
35. [Therapeutic efficacy of 3-year subcutaneous immunotherapy in asthmatic children allergic to mite]. Li L; Hui Y; Qian J; Guo Y; Zhang XL; Zhang XJ Zhongguo Dang Dai Er Ke Za Zhi; 2013 May; 15(5):368-71. PubMed ID: 23676940 [TBL] [Abstract][Full Text] [Related]
36. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501 [TBL] [Abstract][Full Text] [Related]
37. Vaccination during concurrent subcutaneous immunotherapy: safety of simultaneous application. Ullrich D; Ullrich K; Mussler S; Thum-Oltmer S Eur Ann Allergy Clin Immunol; 2015 Jan; 47(1):10-4. PubMed ID: 25599553 [TBL] [Abstract][Full Text] [Related]
38. Systematic review of real-world persistence and adherence in subcutaneous allergen immunotherapy. Park MJ; Kapoor S; Yi J; Hura N; Lin SY Int Forum Allergy Rhinol; 2023 Mar; 13(3):255-264. PubMed ID: 36083799 [TBL] [Abstract][Full Text] [Related]
39. [Compliance and safety evaluation of subcutaneous versus sublingual immunotherapy in mite-sensitized patients with allergic rhinitis]. Zhu L; Lu JH; Xie Q; Wu YL; Zhu LP; Cheng L Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Jun; 45(6):444-9. PubMed ID: 21055319 [TBL] [Abstract][Full Text] [Related]
40. [Causes of stopping subcutaneous specific immunotherapy in asthmatic children]. Huang YN; Huang Y; Dai JH; Yang FF Zhongguo Dang Dai Er Ke Za Zhi; 2012 Sep; 14(9):671-4. PubMed ID: 22989436 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]